As we proposed in our previous study, halofuginone may be used as a promising agent in limiting CAF-driven cancer (Ucaryilmaz Metin and Ozcan, 2022b) since it prevents activation of myofibroblasts through inhibiting TGF-β/Smad3 pathway and limits tumor growth (Pines, 2014). The gene discussed is TGFB1; the disease is cancer.